Par Pharmaceuticals completes third generics deal in 5 months

Par Pharmaceuticals (NYSE: PRX) completed its third generics deal in six months with the $20.5 million acquisition of a drug developer and manufacturer based in India. Edict Pharmaceuticals has 11 abbreviated new drug applications filed with the U.S. Food and Drug Administration. In November, Par Pharmaceuticals completed its $410 million deal to acquire Anchen Pharmaceuticals, […]